Check the records of women who are scheduled to return to your facility for a contraceptive refill or annual well woman exam. Are you seeing empty spots in the schedule?
Two new actions from the Food and Drug Administration (FDA) will impact your practice.
Clinicians now have an approved indication in hand for use of the levonorgestrel intrauterine system Mirena (LNG IUS, Mirena, Bayer HealthCare Pharmaceuticals; Wayne, NJ), to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention.
If medical abortion using mifepristone (Mifeprex, Danco Group) and misoprostol is offered at your facility, be sure to review a new study that asserts the safety of a particular mifepristone/misoprostol regimen.
As the United States gears up to combat the H1N1 flu (also known as swine flu), be sure your practice includes the latest Centers for Disease Control and Prevention (CDC) recommendations for care of pregnant women.
Encouraging news comes from the HIV vaccine research front, where an investigational vaccine regimen tested in a Thailand clinical trial has been shown to be well tolerated and to have a modest effect in preventing HIV infection.
